In conclusion, the established one-step strategy to generate CD19-targeting esCAR T cells that are resistant to alemtuzumab and sensitive to rituximab can be easily implemented in “GMP” protocols for prospective applications in patients bearing CD19+ cancer cells. Here, CD19 is linked to cancer.